CAPOTEN TAB 25MG TABLET

Země: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Aktivní složka:

CAPTOPRIL

Dostupné s:

BRISTOL-MYERS SQUIBB CANADA

ATC kód:

C09AA01

INN (Mezinárodní Name):

CAPTOPRIL

Dávkování:

25MG

Léková forma:

TABLET

Složení:

CAPTOPRIL 25MG

Podání:

ORAL

Jednotky v balení:

100

Druh předpisu:

Prescription

Terapeutické oblasti:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Přehled produktů:

Active ingredient group (AIG) number: 0114954001; AHFS:

Stav Autorizace:

CANCELLED POST MARKET

Datum autorizace:

2011-11-01

Charakteristika produktu

PRODUCT MONOGRAPH
PR
CAPOTEN
*
(CAPTOPRIL)
TABLETS, USP, 12.5, 25, 50 AND 100 MG
ANGIOTENSIN-CONVERTING ENZYME INHIBITOR
Bristol-Myers Squibb Canada
Date of Preparation:
2365 Cote-de-Liesse.
August 28, 1981
Montreal, Canada H4N 2M7
Date of Revision:
*
TM of Bristol-Myers Squibb Canada
November 8, 2006
Control Number: 107808
1
PRODUCT MONOGRAPH
NAME OF DRUG
CAPOTEN
(CAPTOPRIL)
Tablets, USP - 12.5, 25, 50 and 100 mg
THERAPEUTIC CLASSIFICATION
Angiotensin-Converting Enzyme Inhibitor
ACTIONS AND CLINICAL PHARMACOLOGY
CAPOTEN (captopril) is an angiotensin converting enzyme inhibitor
which is used in the treatment of
hypertension and heart failure.
The mechanism of action of CAPOTEN has not yet been fully elucidated.
It appears to lower blood
pressure and be an adjunct in the therapy of congestive heart failure
primarily through suppression of the
renin-angiotensin-aldosterone system; however, there is no consistent
correlation between renin levels
and response to the drug. Renin, an enzyme synthesized by the kidneys,
is released into the circulation
where it acts on a plasma globulin substrate to produce angiotensin I,
a relatively inactive decapeptide.
Angiotensin I is then converted by angiotensin converting enzyme (ACE)
to angiotensin II, a potent
endogenous vasoconstrictor substance. Angiotensin II also stimulates
aldosterone secretion from the
adrenal cortex, thereby contributing to sodium and fluid retention.
CAPOTEN prevents the conversion of angiotensin I to angiotensin II by
inhibition of ACE, a
peptidyldipeptide carboxy hydrolase.
ACE is identical to "bradykininase" and CAPOTEN may also interfere
with the degradation of the
vasopressor peptide, bradykinin. However, the effectiveness of
captopril in therapeutic doses appears to
be unrelated to potentiation of the actions of bradykinin. Increased
concentrations of bradykinin or
prostaglandin E
2
may also have a role in the therapeutic effect of captopril,
especially in low-renin
hypertension.
Inhibition of ACE results in decreased plasma angiotensin II and
inc